Miruvor
Sign up
The short answer

What studies of Mometasone nasal spray (Nasonex) found

18papers on Mometasone nasal spray (Nasonex)
125people in 3 studies testing Mometasone nasal spray (Nasonex) alone
3randomised trials, the strongest kind of study

At a glance, by condition

Long COVID: D Little or no difference

Based on the strongest evidence, randomised trials (very low certainty), for smell and taste loss.

1 outcome rated · see each below

Preventing long COVID: D Little or no difference

Based on the strongest evidence, the randomised trial (very low certainty), for smell and taste loss.

1 outcome rated · see each below

How we got this

Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.

What this means: For long COVID, studies found little or no difference with Mometasone nasal spray (Nasonex). For preventing long COVID, studies found little or no difference with Mometasone nasal spray (Nasonex). If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.

Ask about this treatment

Sign up free to read the rest of what studies found.

You’ll see the full picture: how each symptom fared, every grade with its reasons, side effects, the doses studied and all 18 papers.

The grades, in plain words

Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.

  1. A
    HelpsImprovement, high certainty
    Probably helpsImprovement, moderate certainty
  2. B
    May helpImprovement, low certainty
  3. C
    Might help, very uncertainImprovement, very low certainty
    Mixed resultsStudies disagree
  4. Mometasone nasal spray (Nasonex) · Long COVID is hereMometasone nasal spray (Nasonex) · Preventing long COVID is hereD
    Little or no differenceStudies found little or no difference
  5. F
    HarmsIt made things worse

By symptom and daily life

Long COVID

Smell and taste loss2 studies · 75 people used Mometasone nasal spray (Nasonex) Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; 156 people in all; a small benefit can't be ruled out.

Randomised trials2 studies · 156 people with results

No clear difference in smell and taste loss.

The evidence is very uncertain about the effect of mometasone nasal spray (Nasonex) on smell and taste loss in long COVID. Little or no difference · very low certainty D

  • High risk of bias (RoB 2) in the results that carry most of the weight
  • 156 people in all; a small benefit can't be ruled out

Combination: Mometasone nasal spray (Nasonex) + Smell training (olfactory training)31 randomised

Effect of Olfactory Rehabilitation on the Recovery of Post-Coronavirus Disease Olfactory Dysfunction: A Randomized Controlled Trial. (2024): Association between intervention group and improvement in TIBSIT scores, no clear difference.

Shown, not counted: Mometasone nasal spray (Nasonex) was given together with other treatments.

See the 2 studies
  1. Intranasal Corticosteroid Treatment on Recovery of Long-Term Olfactory Dysfunction Due to COVID-19. (2022)

    People in the study
    80 randomised · 70 analysed
    Dose
    one puff of 0.05% wt/vol, on each side twice per day for 4 weeks
    Outcome
    Smell test score after 2 weeks Iran Smell Identification Test (Iran-SIT)
    Effect
    no clear difference
    Risk of bias
    RoB 2: High
    Randomisation process
    Low
    Deviations from intended interventions
    High
    Missing outcome data
    Low
    Measurement of the outcome
    Low
    Selection of the reported result
    Some concerns
  2. Topical Administration of Mometasone Is Not Helpful in Post-COVID-19 Olfactory Dysfunction. (2022)

    People in the study
    112 randomised · 86 analysed
    Dose
    100 μg in each nostril twice daily
    Outcome
    change in TDI and its subscores Sniffin’ Sticks test
    Effect
    no clear difference
    Risk of bias
    RoB 2: High
    Randomisation process
    High
    Deviations from intended interventions
    High
    Missing outcome data
    High
    Measurement of the outcome
    High
    Selection of the reported result
    Some concerns

Preventing long COVID

Smell and taste loss1 study · 50 people used Mometasone nasal spray (Nasonex) Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; one trial of 100 people found no clear difference; a small benefit can't be ruled out; effect size 1.16 (large).

The randomised trial108 randomised · 100 analysed · 3 weeks · 2 puff (100 μg), once daily in each nostril for 3 weeks

No clear difference in smell and taste loss.

The evidence is very uncertain about the effect of mometasone nasal spray (Nasonex) on smell and taste loss later, when given during acute COVID. Little or no difference · very low certainty D

  • High risk of bias (RoB 2) in the results that carry most of the weight
  • One trial of 100 people found no clear difference; a small benefit can't be ruled out
  • Effect size 1.16 (large)

How big was the difference?

1.16, large. The effect size compares Mometasone nasal spray (Nasonex) with group ii (control group).

See the 1 study
  1. Corticosteroid nasal spray for recovery of smell sensation in COVID-19 patients: A randomized controlled trial. (2021)

    People in the study
    108 randomised · 100 analysed
    Dose
    2 puff (100 μg), once daily in each nostril for 3 weeks
    Outcome
    Smell score after 1 week visual analog scale (VAS)-smell score
    Effect
    no clear difference
    Risk of bias
    RoB 2: High
    Randomisation process
    Some concerns
    Deviations from intended interventions
    Some concerns
    Missing outcome data
    Low
    Measurement of the outcome
    High
    Selection of the reported result
    Some concerns

Side effects

Stopping because of side effects1 study

Doses studied

What researchers used, as the papers print it; not a recommendation.

  1. 1Start

    100 mg at the start

  2. 2Top dose

    Most often 100 mg (1 of 1 studies)

Doses across 1 study

100 to 100 mg.

Each study’s dose, as printed

All papers

  1. Intranasal Corticosteroid Treatment on Recovery of Long-Term Olfactory Dysfunction Due to COVID-19.2022 · placebo trial · 80 randomised · 70 analysed
    Summary

    This double-blind, two-arm, parallel-group, randomized, placebo-controlled trial assessed mometasone furoate nasal spray in non-hospitalized adults with persistent anosmia or severe microsmia for more than 4 weeks due to COVID-19. 80 patients were included; 40 were allocated to mometasone furoate 0.05% wt/vol intranasal spray, one puff on each side twice per day for 4 weeks, and 40 to sodium chloride 0.65% wt/vol nasal spray twice daily for 4 weeks. 70 participants completed follow-up, and 35 in each group were analysed. Olfactory dysfunction was assessed with the Iran Smell Identification Test and a visual analog scale at baseline, 2 and 4 weeks. No significant between-group differences were found in smell test or VAS scores at baseline, 2 or 4 weeks. The changes in both scores from initial to 4 weeks and from 2 to 4 weeks were significantly higher in the mometasone group. At the endpoint, anosmia was reported in 40% of the placebo group and 17.1% of the case group; the frequency of anosmia was 22.9% reduced in the case group relative to the placebo group. No significant differences were observed between groups regarding severity of smell dysfunction. No side effects were noted in the placebo and intervention groups.

  2. Topical Administration of Mometasone Is Not Helpful in Post-COVID-19 Olfactory Dysfunction.2022 · randomised trial · 112 randomised · 86 analysed
    Summary

    This prospective longitudinal case control study at the Technische Universität Dresden, Germany, asked whether adding intranasal mometasone furoate to olfactory training helps persisting olfactory dysfunction after COVID-19. A total of 112 patients were enrolled and randomly assigned; data of 86 patients were analyzed after 26 were excluded due to dropouts, a further SARS-CoV-2 infection, or incompliance. The study group (40 patients) received olfactory training plus mometasone furoate nasal spray, 100 μg in each nostril twice daily with a long applicator, for three months; the control group (46 patients) performed olfactory training only. Olfaction was measured with Sniffin’ Sticks TDI and VAS ratings; follow-up was on average 3.9 months after the first visit. Both groups significantly improved in TDI and all subscores and in VAS ratings. There was no significant difference between groups in the change in TDI and subscores; a one-way MANOVA found no statistically significant differences (F(3, 82) = 0.11, p = 0.91). ΔVAS smell was 2.6 ± 2.2 vs. 2.3 ± 2.0, with no significant intergroup difference. Using an MCID of 5.5, 10 patients (25%) in the study group and 15 (33%) in the control group improved; this was not statistically significant. Side effects were not reported. The authors note the study group had olfactory dysfunction approximately two months longer and the follow-up interval differed by approximately two weeks.

  3. Corticosteroid nasal spray for recovery of smell sensation in COVID-19 patients: A randomized controlled trial.2021 · randomised trial · 108 randomised · 100 analysed
    Summary

    This prospective, randomized, controlled trial was conducted at Benha University Hospital, Egypt, between August and November 2020 in patients who had recently recovered from proven COVID-19 with anosmia or hyposmia. A total of 108 patients were enrolled and randomly allocated; 4 patients in each group were lost and excluded during follow-up, and 50 patients in each group were analyzed (100 total). Group I received mometasone furoate nasal spray, 2 puff (100 μg) once daily in each nostril for 3 weeks, plus olfactory training. Group II received olfactory training only. Smell was rated on a visual analog scale from 0 to 10 initially after recovery/discharge and after 1, 2, and 3 weeks. In both groups, smell scores improved by the end of the third week (P < 0.001). Between groups, smell scores after 1, 2, and 3 weeks showed no statistically significant differences (P-values 0.10, 0.08, and 0.16). Duration until complete recovery was 26.41 ± 7.99 days in group I and 26.15 ± 5.07 days in group II (P = 0.88). Complete recovery after 3 weeks was reported in 31 out of 50 patients (62%) in group I and 26 out of 50 patients (52%) in group II (P = 0.31). Overall, average time to complete recovery was 26.29 ± 6.76 days, and the recovery rate was 57%. Side effects were not reported; withdrawals were not reported. The abstract says one hundred patients were randomly assigned, while the results say 108 were enrolled and randomly allocated.

  4. Different Modalities in the Management of Post-COVID-19 Olfactory Dysfunction.2025 · compared with another group · 120 in the study
    Summary

    This multi-center retrospective case-controlled study included 120 patients with post-COVID-19 olfactory dysfunction (hyposmia or anosmia), divided into four groups of 30. All received olfactory training for 4 weeks; groups also received nasal mometasone furoate, nasal vitamin A, or nasal theophylline, and the control group received isotonic saline nasal irrigation (the abstract describes the control as olfactory training alone). Smell was scored on a visual analog scale from 0 to 10 weekly for one month, and time to complete recovery was recorded. Mean time to complete recovery was 28.97 ± 4.29 days in group A, 25.70 ± 9.20 days in group B, 24.80 ± 6.67 days in group C, and 23.50 ± 7.13 days in group D (P = 0.02*). Smell scores differed between groups after the 1st, 2nd, and 3rd weeks (P-values less than 0.001***), but not after the 4th week (p-value of 0.6). Complete recovery by 4th week ends occurred in 17 of 30 patients (56.6%) in group A, 18 out of 30 patients (60%) in group B, and 21 out of 30 patients (70%) in groups C and D. Harms and withdrawals were not reported.

  5. Role of Topical Intranasal Corticosteroid for Treatment of Post-COVID Olfactory Dysfunction – Our Experiences2023 · no comparison group · 72 in the study
    Summary

    This prospective and descriptive study enrolled 72 COVID-19 patients with post-COVID olfactory dysfunction. All patients received topical intranasal corticosteroids and olfactory training; there was no comparison group. The study was conducted in patients diagnosed with COVID-19 infection by reverse transcription–polymerase chain reaction of the nasopharyngeal swab. The paper reports recovery counts at fixed times: 11 (15.27%) patients recovered after 2 weeks, 34 (47.22%) patients recovered after 3 weeks, and 20 (27.77%) recovered after 4 weeks, out of 72 patients. Three patients lost to follow-up during the treatment period. The paper does not report side effects. No worsening or stopping is described. Limitations are not reported. The authors conclude that intranasal mometasone spray and olfactory training are useful treatment options for post-COVID olfactory dysfunction.

  6. A Potential Novel Treatment for Chronic Cough in Long COVID Patients: Clearance of Epipharyngeal Residual SARS-CoV-2 Spike RNA by Epipharyngeal Abrasive Therapy.2023 · case report · 1 in the study
    Summary

    Why: To describe a case of chronic cough after mild COVID-19 treated with epipharyngeal abrasive therapy (EAT). Who: one 21-year-old man with coughing persisting four months after mild COVID-19; chronic epipharyngitis and chronic sinusitis were diagnosed. Where from: not reported. What was given: EAT once a week for three months, with background low-dose macrolides, carbocisteine, mometasone furoate and nasal irrigation. Compared with: no comparison group. Measured: cough visual analog scale, epipharyngeal inflammation, modified Lund-Mackay score, proinflammatory cytokine expression, and SARS-CoV-2 spike RNA. Found: the VAS score for coughing improved from 7.0 to 0.2; epipharyngeal inflammation improved; the modified Lund-Mackay score changed from 21/54 to 3/54; proinflammatory cytokine expression was reduced; residual SARS-CoV-2 spike RNA disappeared. Harms: bleeding induced by EAT was shown at the first visit and 1, 2, and 3 months; counts and withdrawals were not reported. Limits: the authors state that the mechanism of residual epipharyngeal inflammation and the efficacy of EAT in Long COVID patients remains unclear.

  7. Comparative efficacy and safety of pharmacological interventions for the treatment of long COVID in adults: a systematic review and network meta-analysis2026 · systematic review
    Summary

    A systematic review and network meta-analysis examined pharmacological treatments for long COVID in adults, including trials on COVID-19 symptoms related to long COVID. Records were searched in PubMed/MEDLINE, Cochrane Library, Embase, CINAHL, PsycINFO and Web of Science from the beginning of 2020 to October 31, 2022. The review included 129 studies: 109 RCTs and 20 observational studies. The number of patients enrolled or analysed in the review was not recorded in the extracted data, and treatment duration or follow-up was not reported. Treatments included ivermectin mucoadhesive nanosuspension nasal spray (Aref 2021, 114 patients; Aref 2022, 96 patients), oxaloacetate, anticoagulants, hyperbaric oxygen and others; comparisons were against control (placebo/SOC) or other interventions. Outcomes included mortality, hospital admission, ICU admission, mechanical ventilation, symptom recovery, adverse events, serious adverse events, major bleeding, olfactory scores and thrombotic events. The extracted results contained no between-group result. Recorded harms included higher adverse-event odds with high-dose zinc (OR=21.87, 95%CI [1.25, 383.45]), high-dose vitamin C (OR=56.11, 95%CI [3.26, 966.29]) and tocilizumab (OR=9.64, 95%CI [2.76, 33.75]); major bleeding with treatment-dose anticoagulants (OR=1.86, 95%CI [1.19, 2.89]) and increased ICU admission with propolis. Stopping or dose change was not reported. The authors stated that some results came from a single study or studies with high RoB.

  8. Effects of therapeutic interventions on long COVID: a meta-analysis of randomized controlled trials.2025 · systematic review
    Summary

    This meta-analysis pooled 51 RCTs with 4026 participants with Long COVID, searching PubMed, Cochrane Library, Embase, Web of Science, SPORTDiscus (EBSCO), CINAHL (EBSCO), and Rehabilitation & Sports medicine source (EBSCO) to July 20, 2025. Trials compared exercise training, respiratory muscle training, telerehabilitation, tDCS, olfactory training, steroid sprays, or PEA-LUT with no intervention, standard primary care, or placebo; follow-up ranged from 14 to 180 days. Outcomes included cardiopulmonary function, exercise capacity, fatigue, dyspnea, and olfactory recovery. Exercise training showed significant better 6MWT (MD 83.20; 95% CI 52.04–114.37) and 30sSTS (MD 3.05; 95% CI 1.96–4.13), but no significant difference for HADS-depression, HADS-anxiety, SF-12-PCS, FVC (% predicted), FEV1, VE/VO2, VE, RER, or FEV1/FVC. Respiratory muscle training showed significant better 6MWT (MD 89.54; 95% CI 9.86–169.23) and MIP (cm H2O) (MD 19.69; 95% CI 10.14–29.24), with no significant difference for FVC, FEV1, MFIS, HADS, or MEP. Telerehabilitation showed significant better 6MWT (MD 34.14; 95% CI 2.54–65.74), 30sSTS (MD 1.41; 95% CI 0.67–2.15), and FSS (MD −1.59; 95% CI −2.64 to −0.53). tDCS showed significant lower MFIS-physical (MD −2.29; 95% CI −4.36 to −0.22). Olfactory training and steroid sprays showed no significant differences; PEA-LUT showed significant higher TDI Score (MD 4.66; 95% CI 2.16–7.15). No side-effect or withdrawal counts were reported; the authors noted exercise may pose a risk of symptom exacerbation in post-exertional malaise. They reported high risk of bias in 33 studies and high heterogeneity.

  9. The effectiveness of olfactory training for chronic olfactory disorder following COVID-19: a systematic review.2024 · systematic review
    Summary

    This systematic review searched PubMed, Scopus, Web of Science, EBSCOhost and the Cochrane Library through 01 May 2024 for studies of olfactory training in chronic olfactory disorder persisting for 30 days or longer after COVID-19. Fourteen studies (1.596 participants) were included. Olfactory training alone was reported to improve olfactory function in several studies, though Bérubé et al. observed no effect on objective scores while subjective function improved from 3.8 ± 1.9 to 5.4 ± 1.8 (p = 0.002) and parosmia frequency fell from 16 to 14. Khan et al. reported responders in 37.6% of intervention arms versus 24% of controls, and 55% subjective improvement. In Di Stadio et al., 92% of the PEA-LUT group improved versus 42% of controls; mean TDI rose from 20.6 ± 7.9 to 29.8 ± 7.5, and 56% versus 10% reached a normal TDI. With cerebrolysin, recovery was complete in 61.5% and partial in 17%, with no recovery in the group practising olfactory and gustatory training only. Vitamin A plus OT improved BTT scores (MD = 4.4, 95% CI 1.7 to 7.2), while alpha-lipoic acid showed no significant difference in CCCRC score (p = 0.63). Corticosteroid results were conflicting. The review reports minimal side effects. Authors note only 14 studies and single-study evidence for some adjuvants.

  10. Therapeutic options of post-COVID-19 related olfactory dysfunction: a systematic review and meta-analysis.2023 · systematic review
    Summary

    This systematic review and meta-analysis examined treatments for post-COVID-19 olfactory dysfunction. Eleven studies with 1414 participants were included, and six studies with 916 participants were assessed in the meta-analysis. Treatments included intranasal corticosteroids (INCS), oral corticosteroids (OCS), olfactory training (OT), a PEA 700mg/Luteolin 70 mg supplement, intranasal insulin film and intranasal photobiomodulation. Outcomes included VAS, Sniffin' Sticks identification, TDI, CCCRC and recovery time. For INCS+OT versus OT, VAS showed no significant difference (MD 0.89, 95%CI -1.92 to 3.7, p=0.54, 2 RCTs); Sniffin' Sticks identification showed no significant difference at one month (MD 2, 95%CI -0.66 to 4.66, p=0.139) or two months (MD -1, 95%CI -2.83 to 0.83, p=0.281). For OCS+OT versus OT, TDI showed no statistical difference at one month (MD 3.2, 95%CI -0.13 to 6.52, p=0.06) or two months (MD 2.45, 95%CI -3 to 7.89, p=0.38 in 2 case-controlled studies). OT alone showed statistically significant improvement in smell score (MD 4.68, 95%CI 2.65-6.71, p<0.00001). Betamethasone drops had no significant effect on recovery time versus placebo (Hazard ratio 0.88, 95% CI 0.68-1.14; p=0.31). Two studies reported no side effect related to therapy; LeBon and Saussez reported minor OCS side effects, mainly insomnia, headache, and abdominal discomfort. None reported major adverse effects; no side effects related to OT were reported. Authors' stated limitations were short follow-up periods, a small number of well-designed studies, lack of a control group to assess true OT effects, and quality/heterogeneity.

  11. The Effect of Corticosteroids on Post-Covid-19 Smell Loss: A Meta-Analysis.2023 · systematic review
    Summary

    This systematic review and meta-analysis searched PubMed, ISI Web of Sciences, Scopus and Cochrane Library up to September 2022 for randomized controlled trials of corticosteroids for post-COVID-19 olfactory loss. Six relevant trials with a total population of 712 were included; all administered nasal corticosteroids, and one also used systemic prednisolone plus nasal betamethasone. Controls included saline sprays, placebo drops, olfactory training, or no extra treatment. Outcomes were duration of improvement from anosmia, self-rating olfactory scores, objective smell tests, and frequency of recovered patients. The pooled result showed no significant difference between groups in duration of improvement (mean difference -1.799). Pooled self-rating scores showed no significant effect in favour of the intervention at 2 weeks (0.739) or at study endpoint (1.32). Objective scores were higher in the intervention group at endpoint, but the between-group difference based on IRAN-SIT was not significant (mean difference 1.922; 95%CI 1.319 to 5.163; p-value 0.245). The pooled odds ratio for recovered patients was 1.719 (95%CI 0.896 to 3.298; p-value 0.103). The review notes potential risk for secondary infections with systemic corticosteroids and side effects of OCS and INCs, without counts. The authors state the number of relevant studies was small and assessment methods differed.

  12. Inhaled corticosteroids' effect on COVID-19 patients: A systematic review and meta-analysis of randomized controlled trials.2023 · systematic review
    Summary

    This systematic review and meta-analysis of randomized controlled trials examined whether inhaled corticosteroids (ICS) or intranasal corticosteroids (INC) help patients with COVID-19. Ten included studies had a combined 3168 patients with a mean age of 44, and follow-up between one to four weeks. Treatments were ICS or INC compared with placebo or control. Outcomes were mortality, hospital length of stay, smell scores on a visual analog scale, alleviation of COVID-19-related symptoms, and time to self-reported recovery. The review reported a significant decrease in length of stay in ICS patients over placebo, a significant improvement in VAS smell scores in INC patients after leave-one-out analysis, and significant alleviation of COVID-related symptoms. It found no significant differences in mortality and time to sustained self-reported cure. For harms, an included study reported that inhaled corticosteroids decreased the proportion of participants with moderate to severe adverse events. The authors state that ICS significantly decreases patient LOS and INC may have a role in improving the smell score, but that neither ICS nor INC affects mortality or time to self-reported recovery. They caution that the evidence is inconclusive and the included studies were at moderate risk of bias, with mixed results and small sample sizes.

  13. Interventions for the prevention of persistent post-COVID-19 olfactory dysfunction.2022 · systematic review
    Summary

    This Cochrane review asked whether any treatment given within four weeks of COVID-19 infection can prevent smell problems from persisting. Searching to 16 December 2020, the authors found one completed study of 100 participants, done in Egypt, comparing an intranasal corticosteroid spray (100 µg mometasone furoate in each nostril, once daily) with no intervention; everyone in both groups was also advised to do olfactory training with rose, lemon and cloves. Participants had had smell disturbance for 10 to 28 days at baseline, treatment lasted three weeks, and outcomes were assessed at the end of that period. At three weeks follow-up, 31 out of 50 participants in the intranasal steroid group reported completely normal smell sensation, compared to 26 out of 50 in the control group (risk ratio (RR) 1.19, 95% confidence interval (CI) 0.85 to 1.68; 1 study; 100 participants; very low-certainty evidence). Median sense of smell scores at endpoint were 10 (interquartile range (IQR) 9 to 10) with steroids and 10 (IQR 5 to 10) without (P = 0.16). Few dropouts were reported (7.4% in total), balanced across the two groups. Adverse effects were not reported by the single study included in this review, and no data were available for serious adverse effects, parosmia, taste, quality of life or other adverse effects.

  14. Pharmacologic and Nonpharmacologic Treatment of Long COVID: A Meta-narrative Review2025 · review
    Summary

    This meta-narrative review evaluated pharmacologic and nonpharmacologic treatments for long COVID, defined as persistent symptoms 4 weeks or longer after acute COVID-19. The authors searched English-language articles from November 2019 through December 2023 and included 51 studies. Most included studies reported nonpharmacologic treatments, with fatigue the most prevalent symptom. Interventions described included therapeutic exercise, nutritional supplements, oxygen-ozone autohemotherapy, rehabilitation, molecular hydrogen therapy, hyperbaric oxygen, epipharyngeal abrasive therapy, Qingjin Yiqi granules, pomegranate juice with sumac, remdesivir, antibody-based therapies, and intranasal corticosteroids. Findings varied by study: some reported improvements in fatigue, dyspnea, cognitive symptoms, chest pain, immunodeficiency, or olfactory dysfunction. The review also reported no significant reduction in number or severity of long COVID–related symptoms with high-dose CoQ-10 compared with placebo; no significant difference in symptoms and mortality risks between nirmatrelvir/ritonavir and no treatment groups; smell score differences not statistically significant with corticosteroid nasal irrigation; and no effect of olfactory training on olfactory test scores. In Pehlivan et al., 6 cases were dropped for several reasons. The authors state the evidence is limited and of low quality.

  15. Management of post-COVID-19 olfactory dysfunction.2022 · review
    Summary

    This review presents the literature on management of post-COVID-19 olfactory dysfunction (PCOD), using PubMed/MEDLINE, EMBASE, and Cochrane searches. It summarized studies of olfactory training (OT), intranasal corticosteroids (ICS), and oral corticosteroids (OCS). Denis et al. reported 548 patients with at least 1 month of PCOD; 64% showed clinically significant improvement after a mean OT of 28 days. In Abdelalim et al., 50 patients received MFNS plus OT and 50 received OT alone for 3 weeks; VAS smell scores improved in both groups (P < 0.001), with no significant differences between groups after 1, 2, or 3 weeks. Average time to complete recovery was 26.4 days with MFNS + OT versus 26.2 days with OT alone (P = 0.88); complete recovery was 62% versus 52% (P = 0.31). Le Bon et al. compared 9 patients given a 10-day OCS + OT course with 18 given OT alone and found greater TDI improvement with OCS + OT (P = 0.046). Vaira et al. reported 18 patients had no improvement at 20 days but greater improvement at 40 day evaluations. Singh et al. reported improved anosmia and dysgeusia with ICS over control (p < 0.001). Kim et al. reported recovery rates of 28.2%, 54.8%, and 55.0% at 1-month follow-up (P < 0.001). Hura et al. noted minimal ICS side effects (local irritation, epistaxis); Le Bon et al. reported 3 patients with mild OCS side effects including abdominal pain and insomnia.

A little hope, every Sunday

New recovery stories and data-driven research on ME/CFS and long COVID. Ideas worth considering, and the evidence behind them.

Free · Unsubscribe anytime